Increase in transforming growth factor-β didnot affect trombospondin1 in preeclampsia placentas.
TGF-β levels are significantly higher in preeclampsia placentas compared to normal placentas, indicating altered signaling, but the clinical implications remain unclear.
Where it sits
this study against the rest of the pe 22-28 corpusSummary and findings
This study examined the expression of TGF-β and its signaling proteins in placentas from preeclampsia and normal pregnancies. A total of 66 placental samples (33 normal, 33 preeclampsia) were analyzed for TGF-β, its receptors, SMAD2, and TSp-1 mRNA. Significant differences were observed in TGF-β levels and its receptors between the two groups.
Abstract
<h4>Objective</h4>The abnormalities of the placental growth process are a theory causing pre-eclampsia. Antiangiogenic factors contributed to it, such as thrombospondin-1 (TSp-1) that could stimulate transforming growth factor-beta (TGF-β), or vice versa. Some research showed that an increase in TGF-β did not always figurized its signaling. Therefore, we conducted a study to examine the TGF-β signaling proteins through its receptors and TSp-1 expression in preeclampsia placentas.<h4>Materials and methods</h4>This observational study used 33 normal and 33 pre-eclampsia placental storaged samples, for examination of TGF-β and TGF-βR 1 and 2, SMAD2 using ELISA, and SMAD2 and TSp-1 mRNA using the reverse transcription polymerase chain reaction method. Data were analyzed using SPSS version 20.0, normality test by Kolmogorov-Smirnov, and significancy was analyzed using nonparametric Mann-Whitney test, or t-test for parametric, with confidence interval 95%. Spearman correlation was used for non-parametric data, besides the Pearson correlation for parametric data.<h4>Results</h4>Results showed that there were significant differences between preeclampsia and normal placenta in TGF-β, its receptors, SMAD2, and TSp-1 mRNA. Normal-TGF-β=1.19 (0.713-2.051) pg/mg; preeclampsia-TGFB=2.69 (0.906-10.252) pg/mg; p=0.001; normal-TGFBR1=1.025 (0.622-1.402) ng/mg; preeclampsia-TGFBR1=1.223 (0.372-2.553) ng/mg; p=0.004; Normal-TGF-βR2=0.959 (0.644-1.634) pg/mg; preeclampsia-TGFBR2=1.490 (0.775-3.645) pg/mg; p=0.0001; normal-SMAD2=2.087 (1.279-4.300) ng/mg; preeclampsia-SMAD2=3.508 (1.842-22.489) ng/mg; p=0.0001. The SMAD2 mRNA relative expression (Livax) in the normal placenta was=0.71 (0.03-7.25); pre-eclampsia placenta (PE)=0.49 (0.01-40.71); p=0.075, the normal TSp-1 mRNA expression=1.08 (0.09-5.31); PE=0.21 (0.002-24.06); p=0.002. The correlation test showed a strong correlation between TGF-β with TGFBR1 and 2 in the normal placenta, conversely, there was no correlation in the preeclampsia placenta. There was also no correlation between SMAD2 and TSp-1 mRNA in both normal and pre-eclampsia.<h4>Conclusion</h4>TGF-β signaling in the preeclampsia placenta was changed due to the increased of the protein signaling it self without correlation between TGF-β to its receptors and TSp-1 relative expression.
Background
The study addresses the role of transforming growth factor-β (TGF-β) in preeclampsia, a condition characterized by high blood pressure and potential organ dysfunction during pregnancy. Previous research has suggested that TGF-β may influence various placental factors, including thrombospondin-1 (TSP-1), which is involved in angiogenesis and tissue remodeling. Understanding this relationship is crucial for elucidating the pathophysiology of preeclampsia.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.